Healthcare Industry News: SteadyMed
News Release - September 20, 2012
SteadyMed Therapeutics Inc. Strengthens Management Team With the Addition of Niles Fleischer, Ph.D., General Manager and Rob Zwolinski, VP Operations
SAN FRANCISCO, CA--(Healthcare Sales & Marketing Network) - SteadyMed Therapeutics Inc. ("SteadyMed"), a private drug delivery therapeutics company, today announced that Niles Fleischer has joined the company as General Manager, Israel, and Rob Zwolinski has joined as Vice President, Operations, US.Niles has 30 years of high-tech business experience in the battery, advanced materials and medical device industries. Before SteadyMed he helped launch and was the CEO of NanoMaterials Ltd., where he led the development of several products to international sales. Previously he was President and co-founder of ECR Ltd. based on his inventions for unique batteries and super-capacitors, which are now being sold worldwide. He started his career in the battery industry managing R&D projects at Rayovac in the US and Tadiran in Israel.
Rob has almost 20 years of management experience in the development and commercialization of novel pharmaceutical drug device combination manufacturing and scale up, with a focus on managing aseptic operations both in the US and Europe. He brings to SteadyMed his experience in Contract Manufacturing Organization management, preparation of regulatory documents relating to manufacturing operations of sterile liquid drug device combination products, supply chain management, commercial manufacturing scale up of drug device combination products and oversight of FDA and EU regulatory inspections.
"Both Niles and Rob are great additions to our management team," said Jonathan Rigby, Chief Executive Officer of SteadyMed. "Niles will immediately focus on driving our PatchPump® technology; a novel, prefilled, size efficient and disposable subcutaneous drug delivery system, which includes our Ecell® expanding battery technology, through the development phase as we execute our clinical program for our lead drug product to treat a life threatening orphan disease, as well as securing further collaborations around our unique delivery platform with Biopharmaceutical partners. As a compliment to Niles' activities, Rob will play a key role as we build out our outsourced manufacturing infrastructure to support our PatchPump commercial strategy geared towards our first product launch in 2014. Their expertise in late stage drug delivery system technology development, manufacture and commercialization will further strengthen our strategic and implementation capabilities."
About SteadyMed
SteadyMed Therapeutics, Inc., with offices in the San Francisco Bay Area, CA and Rehovot, Israel, is a private, venture funded drug delivery therapeutics company engaged in the development for commercialization of its PatchPump® technology; a novel, prefilled, size efficient and disposable subcutaneous drug delivery system. The company's range of PatchPumps can be customized to deliver liquid drugs, including biologics, with a wide range of volumes and viscosities, in a consistent and controllable manner.
The company is leveraging the sustainable cost and technological competitive advantages of its PatchPump platform to create a family of products that benefits patients in target markets, which represent the highest value to risk ratios.
PatchPump® is a registered trademark of SteadyMed Ltd.
Source: SteadyMed Therapeutics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
